logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Empagliflozin for Chronic Heart Failure with Preserved Ejection Fraction

< Back

Empagliflozin for Chronic Heart Failure with Preserved Ejection Fraction

Drugs

Cardiovascular Disease and Vascular Surgery

February 2021


Empagliflozin is in clinical development for chronic heart failure and preserved ejection fraction (HFpEF). Heart failure (HF) is a clinical syndrome caused by the impaired ability of the heart to cope with the metabolic needs of the body. This results in breathlessness, fatigue, and fluid retention. The European Society of Cardiology(ESC) defines HFpEF as the presence of signs and symptoms of HF, LVEF ≥50%, elevated natriuretic peptides (NP) levels, and structural heart disease and/or diastolic dysfunction. HFpEF is a growing problem affecting more than half of the patients with HF. HFpEF has a significant morbidity and mortality rate and so far, no treatment has been demonstrated to improve the outcomes in HFpEF.
Empagliflozin is administered orally and usually taken once daily in the morning. Empagliflozin inhibits a protein found in the kidney called sodium-glucose co-transporter-2 (SGLT-2). It blocks glucose absorption in the kidney and increases the amount of glucose excreted in the urine. Empagliflozin significantly reduces the risk of cardiovascular events and heart failure hospitalisation. If licensed, empagliflozin may offer an additional treatment option for patients with HFpEF who currently have no effective treatments available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts